Kalaris Therapeutics (KLRS) Stock Price, Quote, News & History

Comments

Kalaris Therapeutics Inc (KLRS) Stock Price, Quote, News & History

KLRSNASDAQ

Trade with Public

$9.16

-0.05-0.54%

Last update: Mar 12, 12:13 PM

OverviewNews Earnings Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$9.35

Close

-

Volume / Avg.

29.36K / 96.59K

Day Range

$8.67 - $9.57

52 Wk Range

2.14 - 12.90

Market Cap

$171.31M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

18.94%

Days to Cover

11.97

Recent Kalaris Therapeutics Inc News

Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-16.95M

Investing Cash Flow (TTM)

-

Financing Cash Flow (TTM)

18.42M

Free Cash Flow (TTM)

-16.95M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

1.47M

Analyst Trends and Forecast

0

Nov 25

1

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.6

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$96.80M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

4.11

Earnings Yield % (TTM)

-413.10%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.24

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

$9.99M

LT Debt Repayment (TTM)

-

Total Cash

$42.39M

Debt to Equity

0.04

Issuance of Debt (TTM)

$9.99M

Repayment of Debt (TTM)

-

Key Statistics

Open

$9.35

Close

-

Volume / Avg.

29.36K / 96.59K

Day Range

$8.67 - $9.57

52 Wk Range

2.14 - 12.90

Market Cap

$171.31M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

18.94%

Days to Cover

11.97

About

Sector

Health Care

Industry

Biotechnology

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth fa...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Kalaris Therapeutics (KLRS) stock?

A

You can purchase shares of Kalaris Therapeutics (NASDAQ:KLRS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Kalaris Therapeutics (KLRS) competitors?

A

Other companies in Kalaris Therapeutics’s space includes: Molecular Partners AG (NASDAQ:MOLN), ProQR Therapeutics NV (NASDAQ:PRQR), Connect Biopharma Holdings Ltd (NASDAQ:CNTB), Whitehawk Therapeutics Inc (NASDAQ:WHWK) and Sangamo Therapeutics Inc (NASDAQ:SGMO).

Q

What is the forecast, or price target, for Kalaris Therapeutics (KLRS) stock?

A

Kalaris Therapeutics has a consensus price target of $20.67.

Q

What is the current price for Kalaris Therapeutics (KLRS)?

A

The stock price for Kalaris Therapeutics (NASDAQ: KLRS) is $9.16 last updated March 12, 2026 at 12:13 PM EDT.

Q

Does Kalaris Therapeutics (KLRS) pay a dividend?

A

There are no upcoming dividends for Kalaris Therapeutics.

Q

When is Kalaris Therapeutics (NASDAQ:KLRS) reporting earnings?

A

Kalaris Therapeutics does not have any upcoming earnings scheduled.

Q

Is Kalaris Therapeutics (KLRS) going to split?

A

There is no upcoming split for Kalaris Therapeutics.

Q

What sector and industry does Kalaris Therapeutics (KLRS) operate in?

A

Kalaris Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Molecular Partners AG

NASDAQ:MOLN

$4.82

-0.82%

ProQR Therapeutics NV

NASDAQ:PRQR

$1.72

-4.97%

Connect Biopharma Holdings Ltd

NASDAQ:CNTB

$2.80

-7.28%

Whitehawk Therapeutics Inc

NASDAQ:WHWK

$4.02

0.25%

Sangamo Therapeutics Inc

NASDAQ:SGMO

$0.40

-1.64%

Tonix Pharmaceuticals Holding Corp

Insight Molecular Diagnostics Inc

NASDAQ:IMDX

$5.24

-0.19%

Key Statistics

Open

$9.35

Close

-

Volume / Avg.

29.36K / 96.59K

Day Range

$8.67 - $9.57

52 Wk Range

2.14 - 12.90

Market Cap

$171.31M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

18.94%

Days to Cover

11.97

Recent Kalaris Therapeutics Inc News

Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-16.95M

Investing Cash Flow (TTM)

-

Financing Cash Flow (TTM)

18.42M

Free Cash Flow (TTM)

-16.95M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

1.47M

Analyst Trends and Forecast

0

Nov 25

1

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.6

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$96.80M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

4.11

Earnings Yield % (TTM)

-413.10%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.24

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

$9.99M

LT Debt Repayment (TTM)

-

Total Cash

$42.39M

Debt to Equity

0.04

Issuance of Debt (TTM)

$9.99M

Repayment of Debt (TTM)

-

Key Statistics

Open

$9.35

Close

-

Volume / Avg.

29.36K / 96.59K

Day Range

$8.67 - $9.57

52 Wk Range

2.14 - 12.90

Market Cap

$171.31M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

18.94%

Days to Cover

11.97

About

Sector

Health Care

Industry

Biotechnology

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth fa...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry